Jansitin Duo

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Q: What is Jansitin Duo used for?

Jansitin Duo is a prescription oral medication indicated for the treatment of type 2 diabetes mellitus. It combines metformin, a biguanide that improves insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that enhances insulin secretion, to provide complementary glucose‑lowering effects in adults who need additional control beyond diet, exercise, or monotherapy.

Q: How does Metformin Hydrochloride work?

Metformin Hydrochloride primarily reduces hepatic glucose production and increases peripheral glucose uptake, thereby lowering fasting plasma glucose and improving insulin sensitivity. It acts without directly stimulating insulin release, which helps minimize the risk of hypoglycaemia when used alone.

Q: What is the usual dose of Jansitin Duo?

The specific dose of Jansitin Duo is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Q: Is Jansitin Duo safe during pregnancy or breastfeeding?

Safety of Jansitin Duo in pregnancy or lactation has not been fully established. It should only be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Q: How do I order Jansitin Duo from GNH India?

To order Jansitin Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Q: How does Jansitin Duo compare with other antidiabetic options?

Jansitin Duo combines two complementary mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering greater HbA1c reduction than metformin alone. Compared with sulfonylureas, it carries a lower intrinsic risk of hypoglycaemia, and unlike insulin, it is administered orally, making it convenient for many patients.

Q: What are the storage requirements for Jansitin Duo?

Jansitin Duo should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Q: How is Jansitin Duo administered?

Jansitin Duo is taken orally, usually once daily with food to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Q: What are the most serious risks associated with Jansitin Duo?

The most serious risks include lactic acidosis, particularly in patients with severe renal or hepatic impairment, and rare but severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention for symptoms like unexplained muscle pain, rapid breathing, or severe skin rash.

Q: Who should not use Jansitin Duo?

Jansitin Duo is contraindicated in individuals with known hypersensitivity to metformin, sitagliptin, or any excipients, as well as patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or acute or chronic metabolic acidosis, including lactic acidosis. It should also be avoided in patients with a history of pancreatitis.

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jansitin Duo, are a biguanide and DPP‑4 inhibitor presented as an oral tablet for adult use. They treat type 2 diabetes mellitus in patients who need combined glucose‑lowering therapy.

GNH India supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jansitin Duo is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring glycaemic control.

Type 2 diabetes mellitus: improves overall glycaemic control and reduces HbA1c.
In combination with diet and exercise: helps patients achieve target blood‑glucose levels.
When added to metformin monotherapy: provides additional reduction in fasting plasma glucose.

How It Works

Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, prolonging incretin activity and promoting glucose‑dependent insulin secretion. Together they lower blood glucose through complementary pathways without causing hypoglycaemia when used alone.

Side Effects

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Diarrhoea: frequent loose stools, usually transient.
Abdominal discomfort: cramps or bloating.
Headache: mild tension‑type headache.
Upper respiratory tract infection: nasopharyngitis symptoms.
Hypoglycaemia (when combined with insulin or sulfonylureas): dizziness or sweating.

Serious or Rare Side Effects

Lactic acidosis: severe metabolic acidosis, potentially fatal.
Pancreatitis: acute abdominal pain with elevated enzymes.
Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
Hepatic failure: jaundice, elevated liver enzymes.
Anaphylaxis: rapid onset of airway swelling and hypotension.
Renal impairment: worsening kidney function, especially in dehydration.

Precautions & Warnings

Before initiating Jansitin Duo, clinicians should evaluate patient-specific factors and monitor for adverse events.

Renal function: assess baseline eGFR and monitor periodically.
Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment.
Hypoglycaemia: monitor closely if used with insulin or sulfonylureas.
Pregnancy and lactation: prescribe only if benefits outweigh potential risks.
Drug interactions: review concomitant medications for possible interactions.
Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Avoid Interactions

Jansitin Duo may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

Phenformin: co‑administration is contraindicated due to heightened lactic acidosis risk.
Severe renal impairment (eGFR <30 mL/min/1.73 m²): increased metformin accumulation.

Moderate Interactions (Monitor Closely)

Sulfonylureas or insulin: heightened risk of hypoglycaemia.
Iodinated contrast agents: temporary renal function decline may necessitate drug interruption.
Cimetidine: may increase sitagliptin plasma concentrations.
Excess alcohol: can potentiate metformin‑related lactic acidosis.

Frequently Asked Questions

Jansitin Duo is a prescription oral medication indicated for the treatment of type 2 diabetes mellitus. It combines metformin, a biguanide that improves insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that enhances insulin secretion, to provide complementary glucose‑lowering effects in adults who need additional control beyond diet, exercise, or monotherapy.

Metformin Hydrochloride primarily reduces hepatic glucose production and increases peripheral glucose uptake, thereby lowering fasting plasma glucose and improving insulin sensitivity. It acts without directly stimulating insulin release, which helps minimize the risk of hypoglycaemia when used alone.

The specific dose of Jansitin Duo is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety of Jansitin Duo in pregnancy or lactation has not been fully established. It should only be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Jansitin Duo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Jansitin Duo combines two complementary mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering greater HbA1c reduction than metformin alone. Compared with sulfonylureas, it carries a lower intrinsic risk of hypoglycaemia, and unlike insulin, it is administered orally, making it convenient for many patients.

Jansitin Duo should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Jansitin Duo is taken orally, usually once daily with food to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, particularly in patients with severe renal or hepatic impairment, and rare but severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention for symptoms like unexplained muscle pain, rapid breathing, or severe skin rash.

Jansitin Duo is contraindicated in individuals with known hypersensitivity to metformin, sitagliptin, or any excipients, as well as patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or acute or chronic metabolic acidosis, including lactic acidosis. It should also be avoided in patients with a history of pancreatitis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.